Analyst Reco. Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.06 ^USD	-2.75%		-17.19%	+22.54%

Apr. 24	Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating	Nov. 03	MT
Wedbush Trims Karyopharm Therapeutics' PT to $3 From $4, Sees Limited Upside Near Term; Maintains Neutral Rating	Nov. 03	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Equal-Weight Rating	23-08-07	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Outperform Rating	23-08-03	MT
Wedbush Cuts Karyopharm Therapeutics' PT to $4 From $7, Lowers Peak Sales Estimate for Selinexor; Keeps Neutral Rating	23-07-26	MT
Baird Adjusts Karyopharm Therapeutics' Price Target to $10 From $14, Keeps Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Karyopharm Therapeutics Price Target to $10 From $16, Maintains Buy Rating	23-05-05	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Outperform Rating	23-05-05	MT
Wedbush Lifts Karyopharm Therapeutics' Price Target to $7 From $6 After Adding in Valuation for Selinexor in 1L Myelofibrosis, Keeps Neutral Rating	23-04-19	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $6 From $7, Maintains Outperform Rating	23-02-16	MT
Piper Sandler Starts Karyopharm Therapeutics at Overweight With $8 Price Target	23-01-19	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Outperform Rating	23-01-13	MT
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $16 From $18, Maintains Buy Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Market Perform Rating	23-01-10	MT
Wedbush Trims Karyopharm Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $6 From $5, Maintains Market Perform Rating	22-11-04	MT
RBC Upgrades Karyopharm Therapeutics to Outperform From Sector Perform, Boosts Price Target to $10 From $7, Cites 'Improving Uptake' for Xpovio, 'Promising' Mylofibrosis Data	22-11-04	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	22-09-09	MT
Morgan Stanley Cuts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	22-09-09	MT
Baird Lowers Karyopharm Therapeutics Price Target to $14 From $17, Maintains Outperform Rating	22-08-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Analyst Reco.

Filters